SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
FTC Chair Lina Khan prepares to testify during a House Judiciary Committee hearing on July 13, 2023.
"We're thrilled to see the FTC crack down on over a hundred sham Orange Book listings, which keep lifesaving medicines like asthma inhalers and epinephrine prohibitively expensive for those who need them most."
The Federal Trade Commission on Tuesday disputed more than 100 patents held by pharmaceutical companies that make asthma inhalers, EpiPens, and other items listed in the Food and Drug Administration's so-called "Orange Book," which identifies products the agency considers safe and effective.
The FTC sent letters to 10 companies—including AbbVie, AstraZeneca, and Boehringer Ingelheim Pharmaceuticals—notifying them that the commission believes some of their patents are improperly listed in the FDA's Orange Book.
Drug companies have long been accused of abusing the FDA patent listing system to undercut generic competition. In its warning letters to the pharmaceutical companies, the FTC notes that "patents improperly listed in the Orange Book may delay lower-cost generic drug competition."
"By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing generic drug applications," the agency's letters explain. "In addition to delays resulting from such a stay of approval, the costs associated with litigating improperly listed patents may disincentivize investments in developing generic drugs, which risks delaying or thwarting competitive entry. The Supreme Court recognizes that improper Orange Book listings have prevented or delayed generic drug entry since at least the 1990s."
While the letters state that the FTC has chosen to make use of the FDA's formal dispute process to target the allegedly improper listings, the agency said it retains "the right to take any further action the public interest may require," including legal action.
In an interview on NPR Wednesday morning, FTC Chair Lina Khan said that companies are only supposed to list in the Orange Book patents covering active drug ingredients.
"Instead, we have found that firms are listing device patents that have absolutely nothing to do with the active ingredient," said Khan. "So they're instead covering the dispenser cap on a multidose eyedropper or the cap strap on an inhaler, which just keeps the inhalers in place."
"We've identified patents covering these components of devices," Khan added, "and that may in fact be resulting in Americans having to pay hundreds if not thousands of dollars more than they should be."
"Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Consumer advocates applauded the FTC's move as a key step toward challenging the pharmaceutical industry's profit-seeking manipulation of the U.S. patent system.
"We're thrilled to see the FTC crack down on over a hundred sham Orange Book listings, which keep lifesaving medicines like asthma inhalers and epinephrine prohibitively expensive for those who need them most," said Erik Peinert, research manager and editor at the American Economic Liberties Project. "Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Public Citizen also welcomed the FTC's action in a social media post:
The FTC's warning letters to drug companies came after the agency issued a policy statement signaling that it intends to "scrutinize improper Orange Book listings to determine whether these constitute unfair methods of competition."
The statement notes that "patents listed in the Orange Book must claim the reference listed drug or a method of using it."
"Brand drug manufacturers are responsible for ensuring their patents are properly listed," the statement continues. "Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using it. When brand drug manufacturers abuse the regulatory processes set up by Congress to promote generic drug competition, the result may be to increase the cost of and reduce access to prescription drugs."
A report published earlier this year by the American Economic Liberties Project estimated that antitrust violations by the pharmaceutical industry—including shame Orange Book listings—cost U.S. patients, insurers, and federal health programs more than $40 billion in 2019 alone.
Trump and Musk are on an unconstitutional rampage, aiming for virtually every corner of the federal government. These two right-wing billionaires are targeting nurses, scientists, teachers, daycare providers, judges, veterans, air traffic controllers, and nuclear safety inspectors. No one is safe. The food stamps program, Social Security, Medicare, and Medicaid are next. It’s an unprecedented disaster and a five-alarm fire, but there will be a reckoning. The people did not vote for this. The American people do not want this dystopian hellscape that hides behind claims of “efficiency.” Still, in reality, it is all a giveaway to corporate interests and the libertarian dreams of far-right oligarchs like Musk. Common Dreams is playing a vital role by reporting day and night on this orgy of corruption and greed, as well as what everyday people can do to organize and fight back. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. |
The Federal Trade Commission on Tuesday disputed more than 100 patents held by pharmaceutical companies that make asthma inhalers, EpiPens, and other items listed in the Food and Drug Administration's so-called "Orange Book," which identifies products the agency considers safe and effective.
The FTC sent letters to 10 companies—including AbbVie, AstraZeneca, and Boehringer Ingelheim Pharmaceuticals—notifying them that the commission believes some of their patents are improperly listed in the FDA's Orange Book.
Drug companies have long been accused of abusing the FDA patent listing system to undercut generic competition. In its warning letters to the pharmaceutical companies, the FTC notes that "patents improperly listed in the Orange Book may delay lower-cost generic drug competition."
"By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing generic drug applications," the agency's letters explain. "In addition to delays resulting from such a stay of approval, the costs associated with litigating improperly listed patents may disincentivize investments in developing generic drugs, which risks delaying or thwarting competitive entry. The Supreme Court recognizes that improper Orange Book listings have prevented or delayed generic drug entry since at least the 1990s."
While the letters state that the FTC has chosen to make use of the FDA's formal dispute process to target the allegedly improper listings, the agency said it retains "the right to take any further action the public interest may require," including legal action.
In an interview on NPR Wednesday morning, FTC Chair Lina Khan said that companies are only supposed to list in the Orange Book patents covering active drug ingredients.
"Instead, we have found that firms are listing device patents that have absolutely nothing to do with the active ingredient," said Khan. "So they're instead covering the dispenser cap on a multidose eyedropper or the cap strap on an inhaler, which just keeps the inhalers in place."
"We've identified patents covering these components of devices," Khan added, "and that may in fact be resulting in Americans having to pay hundreds if not thousands of dollars more than they should be."
"Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Consumer advocates applauded the FTC's move as a key step toward challenging the pharmaceutical industry's profit-seeking manipulation of the U.S. patent system.
"We're thrilled to see the FTC crack down on over a hundred sham Orange Book listings, which keep lifesaving medicines like asthma inhalers and epinephrine prohibitively expensive for those who need them most," said Erik Peinert, research manager and editor at the American Economic Liberties Project. "Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Public Citizen also welcomed the FTC's action in a social media post:
The FTC's warning letters to drug companies came after the agency issued a policy statement signaling that it intends to "scrutinize improper Orange Book listings to determine whether these constitute unfair methods of competition."
The statement notes that "patents listed in the Orange Book must claim the reference listed drug or a method of using it."
"Brand drug manufacturers are responsible for ensuring their patents are properly listed," the statement continues. "Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using it. When brand drug manufacturers abuse the regulatory processes set up by Congress to promote generic drug competition, the result may be to increase the cost of and reduce access to prescription drugs."
A report published earlier this year by the American Economic Liberties Project estimated that antitrust violations by the pharmaceutical industry—including shame Orange Book listings—cost U.S. patients, insurers, and federal health programs more than $40 billion in 2019 alone.
The Federal Trade Commission on Tuesday disputed more than 100 patents held by pharmaceutical companies that make asthma inhalers, EpiPens, and other items listed in the Food and Drug Administration's so-called "Orange Book," which identifies products the agency considers safe and effective.
The FTC sent letters to 10 companies—including AbbVie, AstraZeneca, and Boehringer Ingelheim Pharmaceuticals—notifying them that the commission believes some of their patents are improperly listed in the FDA's Orange Book.
Drug companies have long been accused of abusing the FDA patent listing system to undercut generic competition. In its warning letters to the pharmaceutical companies, the FTC notes that "patents improperly listed in the Orange Book may delay lower-cost generic drug competition."
"By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing generic drug applications," the agency's letters explain. "In addition to delays resulting from such a stay of approval, the costs associated with litigating improperly listed patents may disincentivize investments in developing generic drugs, which risks delaying or thwarting competitive entry. The Supreme Court recognizes that improper Orange Book listings have prevented or delayed generic drug entry since at least the 1990s."
While the letters state that the FTC has chosen to make use of the FDA's formal dispute process to target the allegedly improper listings, the agency said it retains "the right to take any further action the public interest may require," including legal action.
In an interview on NPR Wednesday morning, FTC Chair Lina Khan said that companies are only supposed to list in the Orange Book patents covering active drug ingredients.
"Instead, we have found that firms are listing device patents that have absolutely nothing to do with the active ingredient," said Khan. "So they're instead covering the dispenser cap on a multidose eyedropper or the cap strap on an inhaler, which just keeps the inhalers in place."
"We've identified patents covering these components of devices," Khan added, "and that may in fact be resulting in Americans having to pay hundreds if not thousands of dollars more than they should be."
"Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Consumer advocates applauded the FTC's move as a key step toward challenging the pharmaceutical industry's profit-seeking manipulation of the U.S. patent system.
"We're thrilled to see the FTC crack down on over a hundred sham Orange Book listings, which keep lifesaving medicines like asthma inhalers and epinephrine prohibitively expensive for those who need them most," said Erik Peinert, research manager and editor at the American Economic Liberties Project. "Big Pharma has been intentionally gaming the United States' drug safety system to block other manufacturers from making and selling the same treatments at lower prices."
Public Citizen also welcomed the FTC's action in a social media post:
The FTC's warning letters to drug companies came after the agency issued a policy statement signaling that it intends to "scrutinize improper Orange Book listings to determine whether these constitute unfair methods of competition."
The statement notes that "patents listed in the Orange Book must claim the reference listed drug or a method of using it."
"Brand drug manufacturers are responsible for ensuring their patents are properly listed," the statement continues. "Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using it. When brand drug manufacturers abuse the regulatory processes set up by Congress to promote generic drug competition, the result may be to increase the cost of and reduce access to prescription drugs."
A report published earlier this year by the American Economic Liberties Project estimated that antitrust violations by the pharmaceutical industry—including shame Orange Book listings—cost U.S. patients, insurers, and federal health programs more than $40 billion in 2019 alone.
Instead of strategically imposing tariffs, Trump has chosen to "give the country the most massive tax increase in its history, possibly exceeding $1 trillion on an annual basis."
As stocks "nosedived" on Thursday, economists, policymakers, and campaigners around the world continued to warn about the impacts of U.S. President Donald Trump's trade war, which includes a 10% universal tariff for imports and steeper duties—that he claims are "reciprocal"—for dozens of countries, set to take effect over the next week.
"This is how you sabotage the world's economic engine while claiming to supercharge it," wrote Nigel Green, CEO of the international financial consultancy deVere Group. "Trump is blowing up the post-war system that made the U.S. and the world more prosperous, and he's doing it with reckless confidence."
As Bloomberg detailed after the president's "Liberation Day" remarks from the White House Rose Garden:
China's cumulative tariff rate of 54% includes both the 20% duty already charged earlier this year, added to the 34% levy calculated as part of Trump's so-called reciprocal plan, according to people familiar with the matter. The European Union's rate is 20% and Vietnam's is 46%, White House documents showed. Other nations slapped with larger tariffs include Japan with 24%, South Korea with 25%, India with 26%, Cambodia with 49%, and Taiwan with 32%.
In Europe on Thursday, "the regional Stoxx 600 index provisionally ended down around 2.7%," while "the U.K.'s FTSE 100 was down 1.6%, with France's CAC 40 and Germany's DAX posting deeper losses of 3.3% and 3.1%, respectively," according to CNBC.
In the United States, CNBC reported, "the broad market index dropped 4%, putting it on track for its worst day since September 2022. The Dow Jones Industrial Average tumbled 1,200 points, or 3%, while the Nasdaq Composite fell 5%. The slide across equities was broad, with decliners at the New York Stock Exchange outnumbering advancers by 6-to-1."
American exceptionalism.
[image or embed]
— Justin Wolfers ( @justinwolfers.bsky.social) April 3, 2025 at 12:14 PM
However, as Economic Policy Institute (EPI) chief economist Josh Bivens noted last week, "because most households depend overwhelmingly on wages from work as their primary source of income and not returns from wealth-holding, the stock market tells us nothing about these households' economic situations."
And Trump's tariffs are expected to hit U.S. households hard, as the cost of his taxes on imports are passed on to consumers.
"Tariffs can be a legitimate and useful tool in industrial policy for well-defined strategic goals, but broad-based tariffs that significantly raise the average effective tariff rate in the United States are unwise," Bivens and EPI senior economist Adam Hersh stressed in a Thursday statement—which also called out Trump for mischaracterizing one of the think tank's 2022 analyses.
"Further, the second Trump administration's rationale, parameters, and timeline for tariffs have been ever-shifting," Bivens and Hersh continued. "As the original post cited by the administration argues, tariffs should not be a goal unto themselves, but a strategic tool to pair with other efforts to restore American competitiveness in narrowly targeted industrial sectors."
Instead of strategically imposing tariffs, Trump has chosen to "give the country the most massive tax increase in its history, possibly exceeding $1 trillion on an annual basis, which comes to $7,000 per household," warned Center for Economic and Policy Research co-founder and senior economist Dean Baker. "And this tax hike will primarily hit moderate and middle-income families. Trump's taxes go easy on the rich, who spend a smaller share of their income on imported goods."
Baker—like various other economists and journalists—also took aim at Trump's claims that the tariffs are reciprocal, explaining:
Trump's team calculated our trade deficit with each country and divided it by their exports to the United States. Trump decided that this figure was equal to that country's tariff on goods imported from the U.S.
Trump's method of calculating tariffs is comparable to the doctor who assesses your proper weight by dividing your height by your birthday. Any doctor who did this is clearly batshit crazy, and unfortunately so is our president. And apparently none of his economic advisers has the courage and integrity to set him straight or to resign.
However, outside Trump's administration, the intense criticism continued to mount, including from groups focused on combating the fossil fuel-driven climate emergency, which also endangers the global economy.
Andreas Sieber, associate director of policy and Campaigns at 350.org, said Thursday that "Trump's tariffs won't slow the global energy transition—they'll only hurt ordinary people, particularly Americans."
"Despite his claims he 'gets' economic policy, his record tells a different story: Tariffs are tanking U.S. stocks and fueling inflation," Sieber added. "The transition to renewables is unstoppable, with or without him. His latest move does little to impact the booming clean energy market but will isolate the U.S. and drive up costs for American consumers."
Allie Rosenbluth, U.S. campaign manager at Oil Change International, similarly emphasized that "Trump's tariffs will hurt working families first and foremost, raising costs for essentials we depend on and threatening to plunge the U.S. economy into a recession. Though Trump pretends to care about the cost of living for ordinary people, his real loyalties lie with his fossil fuel industry donors."
"If he actually cared about energy affordability, he would stop bullying other countries into buying more U.S. liquefied natural gas (LNG), which boosts the fossil fuel industry's profits, but results in increased prices for domestic consumers and pushes us further toward climate catastrophe," she asserted. "The one step countries can take to hit Trump where it hurts most is wean off their dependency on fossil fuels from the United States."
The impact of Trump's new levies won't be limited to working-class people in the United States. Nick Dearden, director of U.K.-based Global Justice Now, pointed out that "Trump has set light to the global economy and unleashed a world of pain, not least on a group of developing countries that will suffer tremendous impoverishment as a result of his punitive tariffs."
"All those affected must come together and stand up to this bully by building a very different international economy that promotes the interests of ordinary people rather than the oligarchs standing behind Trump," he argued. "For all its scraping and crawling, the U.K. got no special treatment here, and the government should learn this lesson fast: They need to stop giving away our rights and protections in a futile effort to appease Donald Trump."
Leaders in the United States are also encouraging resistance to Trump. U.S. Sen. Chris Murphy (D-Conn.) said Wednesday that "this week you will read many confused economists and political pundits who won't understand how the tariffs make economic sense. That's because they don't. They aren't designed as economic policy. The tariffs are simply a new, super dangerous political tool."
Murphy made the case that "the tariffs are DESIGNED to create economic hardship. Why? So that Trump has a straight face rationale for releasing them, business by business or industry by industry. As he adjusts or grants relief, it's a win-win: the economy improves and dissent disappears."
"But as long as we see this clearly, we can stop him. Public mobilization is working. Today, a few Republicans joined Democrats to vote against one set of tariffs," he added, referring to a
resolution that would undo levies on Canadian imports. "The people still have the power."
"If you're a corporation in a favored industry, you can break the law. You can get caught. You can be prosecuted and sentenced with a $100 million fine, and it doesn't matter," said one consumer advocate.
In what could be a U.S. first, President Donald Trump last week pardoned a criminal corporation, a move that largely flew under the proverbial radar amid his pardon spree for white-collar criminals including at least one of his supporters.
On March 28, Trump pardoned HDR Global Trading, the owner and operator of the cryptocurrency exchange BitMEX; company co-founders Arthur Hayes, Benjamin Delo, and Samuel Reed; and former business development chief Gregory Dwyer.
The company and the four men hads each pleaded guilty to one count of violating the Bank Secrecy Act "by willfully failing to establish, implement, and maintain an adequate" anti-money laundering program, as required by law. In January, the U.S. Department of Justice sentenced BitMEX to a fine of $100 million, while the executives were sentenced to criminal probation and ordered to pay civil fines.
While experts noted that Trump acted within his rights to pardon the corporation, there is no known precedent for a president taking such action.
Trump's corporate pardon sends a clear message: “If you’re a corporation in a favored industry, you can break the law. You can get caught. You can be prosecuted and sentenced with a $100 million fine, and it doesn’t matter”
[image or embed]
— Rick Claypool (@rickclaypool.bsky.social) April 2, 2025 at 7:18 AM
Noting the U.S. Supreme Court's highly controversial 2010 Citizens United v. Federal Election Commission ruling—which affirmed corporate personhood and the dubious notion that unlimited outside spending on political campaigns is free speech—Stanford Law School professor Bernadette Meyler told The Intercept that "while we have seen the rise of a trend of treating corporations as persons in other areas of law, we haven't seen that so far in the area of pardoning."
Kimberly Wehle, a professor at the University of Baltimore School of Law and preeminent pardons expert, wrote for The Hill on Tuesday that the BitMEX pardons send the message that "companies involved in financial crimes don't have to worry about accountability under this president, as least when it comes to crypto, for reasons that he has no incentive to ever make known."
"BitMEX can continue its prior criminal practices with federal impunity, and maybe even rely on the pardon to thwart future investigations into related conduct by federal lawmakers or state prosecutors," Wehle added. "The biggest losers in this deal are, once again, the American people, including the more than 77 million who might finally be realizing that they voted for lawlessness last November."
"The biggest losers in this deal are, once again, the American people."
Brandon Garrett, a Duke University law professor specializing in corporate crime and punishment, told The Intercept that the BitMEX pardons are part of a wider pattern of impunity under Trump, who "now seems to be systematically pardoning corporate malefactors left and right without respect, really, to any real serious consideration about the merits of the cases [or] the larger policy implications of issuing these pardons."
As the consumer advocacy watchdog Public Citizen recently noted, "The Trump administration has dropped, withdrawn, or halted investigations and enforcement actions against over 100 corporations in its first two months in office."
Beneficiaries include companies owned or led by Trump donors or allies, including private prison giant GEO Group; Zelle network banks JPMorgan and Bank of America; crypto firms Coinbase, Gemini, Kraken, OpenSea, Ripple, and Robinhood; and Elon Musk's SpaceX.
"Trump's corporate pardons show the president's true base is the billionaire executives and corporate elites lining up to indulge their greed at the trough of Trump's corruption," Public Citizen research director Rick Claypool said last week. "Trump's soft-on-corporate crime approach invites a corporate crime spree and potentially catastrophic abuses for America's consumers, workers, and communities."
Public Citizen co-president Robert Weissman added that the Trump administration's "effective no-enforcement policy against corporations virtually guarantees more financial scams, more workplace discrimination, more poisoning of the air and water, more food contamination, more fraud, more disease, and more preventable death."
"No parliamentary tricks will change the fact that Trump, Musk, and his allies in Congress are trying to give a huge handout to the ultrawealthy while forcing the rest of us to foot the bill," wrote one watchdog.
Watchdogs and other critics swiftly denounced a budget blueprint unveiled by Senate Republicans on Wednesday that endeavors to get the GOP one step closer to delivering additional spending and trillions in tax cuts desired by U.S. President Donald Trump.
Observers are also condemning Republicans' plans to skirt the Senate parliamentarian and use a controversial gimmick to make an extension of provisions from Trump's 2017 Tax Cuts and Jobs Act look "free"—even the cost of extending those cuts would be nearly $4 trillion over 10 years, and the Senate proposal includes a total of $5.3 trillion in tax cuts.
"Let's be clear: Trump and his allies in Congress are cooking the books in broad daylight. They don't want Americans to know that their scam of a tax bill, which gives trillions in giveaways to their billionaire and corporate donors, costs over $5 trillion," said David Kass, the executive director of the advocacy group Americans for Tax Fairness (ATF), in a statement on Wednesday.
Lisa Gilbert, co-president of the watchdog group Public Citizen, referenced Trump's billionaire adviser Elon Musk when declaring that "Republicans have chosen to prioritize the Trump-Musk agenda of picking the pockets of everyday people to shower billionaires with tax giveaways."
The Senate budget blueprint would increase the country's debt limit by $5 trillion and permanently extend tax cuts passed through Trump's 2017 Tax Cuts and Jobs Act, according to NPR.
Extending those tax cuts would primarily benefit the wealthy. According to a 2024 analysis from the Tax Policy Center, households making about $450,000 or more a year would receive nearly half of the benefits of extending key provisions of Trump's 2017 tax cuts.
According to a February report from ATF, the wealthiest Republicans on tax writing panels could save themselves millions through extending these cuts, particularly by keeping in place a higher estate tax exemption.
The Senate budget blueprint includes the $4.5 trillion tax plan passed by the House of Representatives in February, according to NPR. The House plan is crafted so the only way to achieve the requirements of the budget resolution is to enact steep cuts to Medicaid. The budget resolution also makes cuts to the Supplemental Nutrition Assistance Program (SNAP) all but certain.
Sharon Parrott, the president of the nonpartisan research organization the Center on Budget and Policy Priorities, framed the Senate budget plan like this: "Congress is speeding down a path to a deeply harmful budget and tax 'reconciliation' bill that showers tax cuts on millionaires, billionaires, and corporations—and pays for it in part by raising healthcare and food costs through cuts in Medicaid and SNAP, increasing hardship and leaving millions without health coverage."
In order to move the legislation forward, Senate Republicans are planning on bypassing the Senate parliamentarian—who has sway over whether legislation can be sped up through the filibuster-free reconciliation process—on a crucial budgeting matter, according to Wednesday reporting from The New York Times.
By asserting that Sen. Lindsey Graham (R-S.C.), chairman of the Senate Budget Committee, can decide the cost of legislation Republicans are angling not to get the parliamentarian's sign-off on their claim that extending the tax cuts will be free, per the Times.
The GOP is attempting to make the tax cut extension appear free by using the "current policy" baseline rather than the "current law" baseline. One expert who spoke to the Times compared it to "taking an expensive weeklong vacation and then assuming you can spend an extra $1,000 per day forever since you are no longer staying at the Plaza."
A trio of experts writing for the Center for American Progress wrote that the approach is unprecedented in the past five decades since the Congressional Budget Office was formed and lawmakers acted within the current budget framework.
"Don't be fooled: the only way Senate Republicans can pay for their tax cuts to the wealthy is by taking a chainsaw to Medicaid, school lunches for kids, and driving up the cost of groceries and housing," said the executive director of the watchdog Accoutable.US, Tony Carrk, on Wednesday. "The math doesn't add up, and no parliamentary tricks will change the fact that Trump, Musk, and his allies in Congress are trying to give a huge handout to the ultrawealthy while forcing the rest of us to foot the bill."
Republicans narrowly control both chambers of Congress. According to Politico, the Senate will vote as soon as Thursday to consider the blueprint, which if adopted, would allow the House to try to adopt it before breaking for a two week recess.